The old saying an aspirin a day keeps the doctor away seems to apply for certain cancers now. Researchers reported that aspirin and other NSAIDs decrease the risk of progression of the most aggressive form of Barrett's esophagus to esophageal cancer. In a study NSAID users took the drug at least once a week for six or more months any time during follow-up, regardless of daily frequency, duration, or type, the researchers reported. Galipeau and colleagues also found that those with three or more of the biomarkers who used aspirin or other NSAIDs had a 30% risk of esophageal cancer after 10 years, while those with the same biomarkers who did not use NSAIDs had a 79% risk of developing cancer within a decade.

The vast majority of patients in this cohort had gastroesophageal reflux disease and were undergoing therapy, mainly with proton-pump inhibitors. It is unclear how the frequency or severity of symptoms may have affected NSAID use by participants, the researchers said. However, to their knowledge, they said, symptoms from reflux are not associated with intermediate endpoints or cancer in Barrett's esophagus, so it is unlikely that symptoms could explain the association of NSAID use with reduced risk of esophageal cancer. The findings may help identify patients who may benefit most from a very cost-effective, noninvasive therapy in the form of aspirin or NSAIDS.